BridgeBio Pharma, Inc. (BBIO)
- Previous Close
33.26 - Open
33.33 - Bid 24.00 x 200
- Ask 42.57 x 200
- Day's Range
32.90 - 33.76 - 52 Week Range
21.62 - 39.54 - Volume
809,327 - Avg. Volume
3,362,173 - Market Cap (intraday)
6.318B - Beta (5Y Monthly) 1.15
- PE Ratio (TTM)
-- - EPS (TTM)
-3.56 - Earnings Date Jul 30, 2025 - Aug 4, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
58.78
BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. The company offers Attruby, a next-generation oral small molecule near-complete TTR stabilizer for the treatment of cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; low-dose infigratinib, a treatment option for children living with hypochondroplasia, a skeletal dysplasia closely related to achondroplasia which is in Phase 2/3. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 3 clinical trial for treating autosomal dominant hypocalcemia type 1, or ADH1; and BBP-418, a glycosylation substrate pro-drug that is in Phase 3 clinical trial for treating limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). In addition, it engages in developing products for mendelian, oncology, and gene therapy diseases. In addition, it engages in developing products for mendelian, oncology, and gene therapy diseases. The company has license and collaboration agreements with the Alexion Pharma International Operations Unlimited Company, Leland Stanford Junior University and Leidos Biomedical Research, Inc., and Novartis International Pharmaceutical Ltd. BridgeBio Pharma, Inc. was founded in 2015 and is headquartered in Palo Alto, California.
bridgebio.comRecent News: BBIO
View More
Performance Overview: BBIO
Trailing total returns as of 5/14/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: BBIO
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: BBIO
View MoreValuation Measures
Market Cap
6.32B
Enterprise Value
7.63B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
49.32
Price/Book (mrq)
--
Enterprise Value/Revenue
59.91
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-48.27%
Return on Equity (ttm)
--
Revenue (ttm)
127.42M
Net Income Avi to Common (ttm)
-667.97M
Diluted EPS (ttm)
-3.56
Balance Sheet and Cash Flow
Total Cash (mrq)
540.6M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-261.2M
Research Analysis: BBIO
View MoreResearch Reports: BBIO
View MoreBridgeBio Earnings: Positive Outlook With Strong Launch of Attruby; Raising Fair Value Estimate
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis) , is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.
RatingPrice TargetBridgeBio Earnings: Solid Fourth-Quarter Results Driven by Attruby’s Commercial Launch
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis) , is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.
RatingPrice TargetBridgeBio: Shares Surge as Attruby Gains FDA Approval; Slightly Raising Our Fair Value Estimate
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis) , is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.
RatingPrice TargetBridgeBio: Shares Surge as Attruby Gains FDA Approval; Slightly Raising Our Fair Value Estimate
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis) , is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.
RatingPrice Target